Epstein-Barr virus associated lymphoproliferative disorder Clinical Trials EU — 2 Studies

Filter these 2 trials by phase, country, sponsor and more.

Open-label Phase 2 of tabelecleucel in Subjects with Epstein Barr Virus associated Diseases (EBVision) Recruiting

2024-516623-14-00 4 2021-03-17 "EBV+ primary imunodeficiency lymphoproliferative disease (LP"
A study for subjects after organ or cell transplantation after failure of prior treatment Recruitment ended

2024-516622-57-00 5 2020-05-06 "Epstein-Barr Virus-Associated Post-Transplant Lymphoprolifer"

Showing 1–2 of 2 trials